View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsIdogen 過去の業績過去 基準チェック /06Idogenの収益は年間平均-11.4%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間32.4% 19.3%割合で 増加しています。主要情報-11.39%収益成長率51.35%EPS成長率Biotechs 業界の成長0.71%収益成長率19.29%株主資本利益率-2,166.60%ネット・マージン-5,712.97%次回の業績アップデート23 Aug 2023最近の業績更新お知らせ • Nov 26+ 2 more updatesIdogen AB (publ) to Report First Half, 2023 Results on Aug 23, 2023Idogen AB (publ) announced that they will report first half, 2023 results on Aug 23, 2023すべての更新を表示Recent updatesお知らせ • Jul 08Nasdaq Stockholm Decides to Delist the Shares of Idogen from Nasdaq First North Growth MarketOn July 7, 2023, Idogen AB issued a with information that the Lund District Court had declared the company bankrupt. According to item 8.2.6 of the Nasdaq First North Growth Market Rulebook, the exchange may decide to delist the financial instruments of an issuer if the issuer is subject of insolvency. With reference to the above, Nasdaq Stockholm AB has decided to delist the shares of Idogen AB from Nasdaq First North Growth Market with immediate effect.お知らせ • Nov 26+ 2 more updatesIdogen AB (publ) to Report First Half, 2023 Results on Aug 23, 2023Idogen AB (publ) announced that they will report first half, 2023 results on Aug 23, 2023お知らせ • Nov 22Idogen AB (publ) Appoints Jan Holgersson to Its Board of DirectorsIdogen AB (publ) announced that Jan Holgersson, who has served for several years as scientific adviser to the company, has agreed to strengthen the company’s Board of Directors in the role as co-opted Board member. Jan Holgersson is a professor of Transplant Immunology at Gothenburg University, the Medical Director of the Tissue Typing and Stem Cell Laboratories at Sahlgrenska University Hospital in Gothenburg, where he was also formerly the Head of Clinical Immunology and Transfusion Medicine. His research focuses on understanding the immunological mechanisms that underlie the rejection of transplanted organs and tissues. Another important initiative has been supporting the development of diagnostics for detection and semiquantification of antibodies against the ABH blood group antigens and other tissue antigens (non-HLA). Jan Holgersson is also Chairman of the Board of VERIGRAFT AB, a Swedish biotech company. Jan has been part of the company’s efforts at a detailed survey of the mechanisms of action for the company’s technology platform.Board Change • Nov 16High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 4 experienced directors. No highly experienced directors. Founder & Chairman of the Scientific Advisory Board Leif Salford is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Nov 02Idogen AB Announces Board ChangesIdogen AB announced that Agneta Edberg has been elected as new Chairman of the Board since the current Chairman of the Board, Joakim Söderström, has requested to resign from the Board of Directors at his own request as he has accepted a new position that is incompatible with being active in the Board of Directors of a public company. In addition, Niklas Wallett, who was elected to the Board of Directors at the same time as Joakim Söderström, has also requested to resign from the Board of Directors at his own request. In September 2022, both Joakim Söderström and Niklas Wallett were elected to the Board of Directors of Idogen. Joakim Söderström was elected to be the Chairman of the Board, replacing Agneta Edberg. Joakim Söderström has now requested to resign from the Board of Directors at his own request as he has accepted a new position that is incompatible with being active in the Board of Directors of a public company and he will resume his role as a shareholder. In addition, Niklas Wallett has also requested to resign from the Board of Directors at his own request to resume his role as a shareholder. Due to the above changes, the Board of Directors of Idogen has elected Agneta Edberg as new Chairman of the Board, effective from today. As consequence of these changes, the Board of Directors consists of Agneta Edberg, Chairman, Sharon Longhurst and Christina Herder, meaning that the Board of Directors retains a quorum. Proposal for election of a new Board of Directors will be submitted by the Nomination Committee in connection with the announcement of the notice of the Annual General Meeting 2023, at the latest.お知らせ • Oct 15Idogen AB (Publ) Announces First Patient Enters Idogen's Hemophilia Study Under the Ido 8 ProgramIdogen AB (publ) announced that the first patient has been included in the Phase I/IIa clinical trial with ItolDC-028, the company's cell therapy that is part of its IDO 8 program. The patient was included at Oslo University Hospital, where the trial will be carried out under the management of professor and chief physician Pål Andre Holme. The patients that will be included in the study all have hemophilia A and should have developed antibodies to their treatment with factor VIII. They should also have undergone unsuccessful immune tolerance induction (ITI) treatment and still have inhibitors against factor VIII. The patient who has been enrolled in Norway will now undergo planned tests ahead of the apheresis process, the purpose of which is to collect the patient's white blood cells which are then used to manufacture the cell therapy. The white blood cells will be sent to the company's partner, Radboud University Medical Center (RUMC) in the Netherlands, where they will be processed using the company's patented technology. The overall objective of the therapy is toinduce a tolerance to factor VIII, which in turn means the patient can once again undergo factor VIII treatment without any problems.お知らせ • Sep 28Idogen AB (publ) Announces Board ChangesOn September 6, 2022, Idogen held an Extraordinary General Meeting to elect Joakim Söderström as new chairman and Niklas Wallett to the board. They are both significant shareholders in Idogen and will now take an active role on the board to take the company to the next level. BioStock had a chat with newly elected Chair Joakim Söderström about his new role and his expectations.お知らせ • Sep 21Idogen Receives Approval from the Regional Ethics Committee to Conduct Clinical Phase I/IIa StudyIdogen AB (publ) announces that the company has received approval from the Norwegian REK (Regionale komiteer for medicinsk og helsefaglig forskningetikk) in Oslo to conduct the clinical phase I/IIa study of their drug candidate within the IDO 8 program for patients suffering from hemophilia who have developed antibodies against their life-saving factor VIII treatment. The approval means that study activities can begin at the clinic and that the first patient can be enrolled in the study within short. Idogen has now received approval from the ethics committee in Oslo to conduct the company's phase I/IIa study in hemophilia with the drug candidate, ItolDC-028. The study is conducted under the leadership of professor and senor physician Pål Andre Holme. Shortly, the first patient will be able to be enrolled, after which the first step in the treatment will be possible to be carried out.お知らせ • Sep 13Idogen Appoints Christina Herder as Acting CEOIdogen appointed Christina Herder as new acting CEO by the board of directors. Herder has for the past five years been a board member of Idogen and also has more than 30 years of experience in several senior positions in the pharmaceutical industry.お知らせ • Sep 07Redeye Updates Their Analysis of Idogen as Company Approaches Clinical PhaseRedeye updated their analysis of Idogen as company approaches clinical phase Idogen AB (publ) is a company that is developing tolerogenic cell therapies with the aim to treat conditions or diseases caused by an unwanted immune response in the patient. As the company now approaches clinical phase with its most advanced development program IDO 8, Redeye is intensifying their coverage of Idogen and have published an updated analysis of Idogen AB. In summary, Redeye's report describes Idogen as a company developing novel treatments where there are large unmedical needs. In the most advanced program, IDO 8, the company has developed a cell therapy for patients with Hemophilia A, who have developed antibodies, a k a "inhibitors". Against their vital factor VIII treatment. The first clinical study within this program has, as previously communicated, obtained regulatory approval in both Sweden and Norway. The first patient is planned to be included in this phase 1/2a study during autumn. Another example that is highlighted in the analysis of the company's platform is the IDO T-program, where the researchers in the company is working to develop a new cell therapy for patients that are to have a kidney transplant. There is a risk that the patient develops an organ rejection and is currently treated, to minimize the risk, with immunosuppressants for long periods, which may lead to serious side effects. Example of side effects can be e.g. severe infections or cancer. A pre-treatment with Idogen's cell therapy, could counteract the undesired immune reponse that leads to a rejection. There are several more potential uses for cell therapies from the company as the technology platform is adaptable; as the tolerogenic cells may be adapted to several different types of antigens causing problems for the patient. The usage can thus be expanded to other diseases where the immune system attacks tissues or transplants in an unwanted way.お知らせ • Aug 11Idogen AB (Publ) Announces CEO Executive ChangesIdogen AB (publ) announced that Anders Karlsson has decided to leave the company to move on to a CEO role in another Swedish biotechnology company. He will remain in his current position until 1 September 2022; the board is now starting a process to recruit a successor. Christina Herder, who has been a board member of the company for more than five years, has been appointed acting CEO while the recruitment of a new CEO is underway. She will retain her role on the board during this time.お知らせ • Jul 29Idogen AB (publ) is Preparing to Start Clinical Phase 1/2A Study with IDO 8 in NorwayIdogen AB (publ) is working intensively on the preparations for the company's first clinical study with the cell therapy IDO 8 in patients with severe hemophilia A and is meeting a great deal of commitment at participating study centers. In Norway, the company's clinical trial center has come a long way in preparations for the study. Idogen has previously received approval from both the Swedish and the Norwegian Medicines Agency to start the study, and in Norway, patients who are suitable for inclusion have now been identified. Professor Pål Andre Holme, senior physician at Oslo University Hospital and clinical investigator in Idogen's study, says in an interview with BioStock that he expects to soon be able to start the study and hopes to start after the summer. What remains in Norway is an approval from the local ethics committee. The approvals the company received to start the study in Sweden and Norway are now being used to obtain a combined approval that includes all countries in the EU. For the UK, the approval process is based on the work done previously in Sweden and Norway.Board Change • Apr 27No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 5 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Founder, Chairman of the Scientific Advisory Board & Director Leif Salford is the most experienced director on the board, commencing their role in 2009. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Apr 20Idogen AB (publ) Announces Study Approval in Norway and SwedenIdogen AB (publ) has received the go-ahead from both the Swedish and Norwegian Medical Products Agencies to initiate a clinical phase I/IIa study with the cell therapy IDO 8 in hemophilia A. The study's primary purpose is to show that the treatment is safe and to obtain preliminary data on the potential treatment effect.お知らせ • Apr 13+ 1 more updateIdogen Strengthens the Organization Before the Clinical Development PhaseIdogen (publbl) announced that the organization has been strengthened with several leang key roles before the companany's most advanced drug candidate enters the clinical development phase. The management team is thus expanded with competence and experience in both early drug development and clinical trials. In March 2022, Idogen received approval from the Medical Products Agency to initiate a clinical phase 1/2a study in the development program IDO8, a potentially revolutionary cell therapy for patients with severe hemophilia A who have developed antibodies to their vital treatment with coagulation factor VIII. The study will be conducted at several testing centers in Europe and before the start, the company is now strengthening the organization with three new employees.お知らせ • Apr 11Idogen AB (Publ) Receives Approval from the Norwegian Medicines Agency, Noma, for the Start of Clinical Phase 1/2A Study with IDO 8Idogen AB (publ) received approval from the Norwegian Medicines Agency, NoMA, to ben recruitment for its clininical phase 1/2a study with IDO 8, a completely new type of cell therapy for patients with severe hemophilia A who have developed antibodies to their treatment with coagulation factor VIII. The Swedish Medical Product Agency has already previously approved the phase 1/2a study and patient recruitment in Sweden will begin as soon as the authority has formally approved the local trial center where the study is to be carried out. The approval from NoMA now gives the go -ahead to start patient recruitment in Norway as well. The plan is for the study to be carried out in several European countries. Idogen's cell therapy IDO 8 is tailored for each individual patient in a GMP-certified facility at the company's Dutch manufacturing partner Radboud University Medical Center (RUMC). The study has been designed in dialogue with the regulatory authorities in the Nordic countries and the goal is to evaluate the safety of IDO 8 and to follow signals of treatment effect in patients.お知らせ • Mar 29Idogen Receives Approval from the Swedish Medical Products Agency for the Clinical Phase I/IIa Study with IDO 8Idogen recently announced that they have received approval from the Swedish Medical Products Agency for the clinical phase I/IIa study with IDO 8. The cell therapy is aimed at patients with severe haemophilia A who have developed antibodies to their substitution therapy with coagulation factor VIII. BioStock contacted Professor Jan Astermark, Principal Investigator in the clinical study, to find out more about the unmet medical need of these patients.お知らせ • Feb 15Idogen AB (publ) has completed a Composite Units Offering in the amount of SEK 50.425465 million.Idogen AB (publ) has completed a Composite Units Offering in the amount of SEK 50.425465 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 16,478,910 Price\Range: SEK 3.06 Transaction Features: Rights Offeringお知らせ • Jan 12Idogen AB (Publ) Submits Application to Norwegian Medicines Agency to Begin Clinical Phase 1/2A Study of the Advanced Cell Therapy Treatment IDO 8 in NorwayIdogen AB announced that in addition to its Swedish application, it has also sub-mitted an application to the Norwegian Medicines Agency, NoMA, to be able to begin its clinical phase 1/2a study of the company's most advanced cell therapy treatment IDO 8 in Norway. IDO 8 aims to create tolerance for factor VIII and thus enable ongoing substitu-tion treatment with coagulation factor VIII - a life-saving drug treatment for hemophilia A against which many patients develop antibodies. The aim of the planned phase 1/2a study, which was designed in close dialogue with clinical experts and regulatory authorities in the Nordic region, is to evaluate the safety of IDO 8 and follow signals of treatment effect in patients. Given that the application is approved by NoMA without adjustments, the study is planned to start during the second quarter of 2022. Idogen's cell therapy is tailored for each individual patient in a GMP-certified facility at the company's manufacturing partner Radboud University Medical Center (RUMC) in the Netherlands. The therapy is based on the patient's own cells and is expected to have a favorable safety profile and the opportunity to create a long-term treatment effect.お知らせ • Dec 22Idogen Submits Clinical Trial ApplicationIdogen submitted a clinical trial application to the Swedish Medical Products Agency to initiate a clinical phase I/IIa study with the cell therapy IDO 8 in patients with haemophilia A who have developed antibodies to their treatment. Once the application has been reviewed and approved, the study can be initiated, which is expected to be in the second quarter of 2022.お知らせ • Dec 18Idogen AB Submits an Application to the Swedish Medical Products Agency to Initiate A Clinical Phase 1/2A Study of the Cell Therapy Treatment IDO 8Idogen AB announced that it has submitted a clinical trial application to the Swedish Medical Products Agency (MPA) to begin its clinical phase 1/2a study of the company's most advanced cell therapy treatment, IDO 8. IDO 8 aims to create tolerance to factor VIII, thereby enabling ongoing substitution treatment withcoagulation factor VIII a vital treatment in hemophilia (hemophilia A) against which many patients develop antibodies. The aim of the planned phase 1/2a study, which has been designed in close dialogue with the regulatory authorities in the Nordic countries, is to evaluate the safety of IDO 8 and to monitor patients forsignals of a clinical treatment effect. The planned start date of the trial is dependent on the MPA review process, but it is anticipated the study, once approved, will be initiated in the second quarter of 2022. Idogen's cell therapy is tailored for each individual patient in a GMP-certified laboratory at the company'smanufacturing partner Radboud University Medical Center in the Netherlands. The therapy is based on the patient's own cells and is therefore expected to have a favorable safety profile and to create a long-term treatment effect. The company is now initially submitting the application to start the phase 1/2a study to theMPA.お知らせ • Dec 08Idogen AB (publ) Completes the Optimization of the GMP Manufacturing Process for the First Clinical Study with Its Tolerogenic Cell Therapy IDO 8Idogen AB announces that it has successfully maximized the antigen levels in the cell therapy IDO 8 that the body should learn to recognize and tolerate. This is considered to be an important feature in order to obtain a good treatment effect. The IDO 8 treatment is aiming to create tolerance for ongoing substitution treatment with coagulation factor VIII, a vital drug for hemophilia (hemophilia A) which in many patients is inactivated as a result of undesired immune reactions. The company will shortly submit a clinical trial application to start the first study in patients. Subject to required regulatory approvals, the study is planned to start during the second quarter of 2022. A successful tech transfer and scale-up of the manufacturing process for Idogen's cell therapy has been followed by extensive work aimed at optimizing, documenting and qualifying the manufacturing process for the planned first clinical study. The company's manufacturing partner, Radboud University Medical Center (RUMC) in the Netherlands, a manufacturer of cell therapies, has now optimized and qualified the manufacturing process, achieving product properties equivalent to those generated when IDO 8 was manufactured in Idogen's own research laboratory. This has been achieved through an effective collaboration between RUMC and Idogen. Idogen's cell therapy will now be tailored for each individual patient in a GMP-certified laboratory at the company's partner Radboud University Medical Center in the Netherlands. The proprietary treatment is based on patients own cells, differentiated into dendritic cells using Idogen's unique tolerance inducers and the specific antigen that the body's immune system must learn to tolerate.Recent Insider Transactions • Oct 06CEO & MD recently bought kr144k worth of stockOn the 5th of October, Anders Karlsson bought around 70k shares on-market at roughly kr2.06 per share. This was the largest purchase by an insider in the last 3 months. This was Anders' only on-market trade for the last 12 months.お知らせ • Feb 26Idogen AB Receives Confirmation the European Patent Office Intends to Grant A Patent ApplicationIdogen AB has received confirmation that the European Patent Office (EPO) intends to grant a patent application which supports and covers the company's tolerogenic cell therapy's application to the severe bleeding disorder, hemophilia A. This patent application was submitted in 2016 and will provide additional protection to the broader patent application for Idogen's technology which in December 2020 was extended via an International (PCT) application. When the patent (Patent Application No. EP16710978.4) is granted, it will protect this technical space until 2036. The final grant of this patent by the EPO is expected to occur within two to three months following the completion of routine formalities by Idogen. A similar application is pending in the US. The granted patent will provide important complementary protection to that sought via the International (PCT) application for Idogen's new, innovative method for cell therapy that was filed in December 2020. That patent application will, following grant, provide the company with a patent protection and market exclusivity until 2040.Is New 90 Day High Low • Feb 23New 90-day low: kr2.99The company is down 16% from its price of kr3.55 on 25 November 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.お知らせ • Feb 09Idogen AB (publ) Announces Executive ChangesIdogen AB (publ) announced that Åsa Schiött was appointed new Chief Scientific Officer (CSO), Christina Brattström new Chief Medical Officer (CMO) and Vicky Venizelos Chief Regulatory Officer (CRO).Is New 90 Day High Low • Dec 28New 90-day low: kr3.08The company is down 41% from its price of kr5.18 on 29 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 12% over the same period.Is New 90 Day High Low • Dec 08New 90-day low: kr3.27The company is down 42% from its price of kr5.68 on 09 September 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.Is New 90 Day High Low • Nov 19New 90-day low: kr3.63The company is down 42% from its price of kr6.24 on 20 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 10.0% over the same period.Is New 90 Day High Low • Oct 16New 90-day low: kr3.98The company is down 43% from its price of kr6.98 on 17 July 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.Is New 90 Day High Low • Sep 28New 90-day low: kr5.06The company is down 5.0% from its price of kr5.30 on 30 June 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period.収支内訳Idogen の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OM:IDOGEN 収益、費用、利益 ( )SEK Millions日付収益収益G+A経費研究開発費31 Mar 231-4444031 Dec 220-4847030 Sep 223-5052030 Jun 2211-4150031 Mar 2212-3950031 Dec 2114-3951030 Sep 2113-3344030 Jun 217-3338031 Mar 218-3137031 Dec 208-2733030 Sep 207-2733030 Jun 206-2934031 Mar 205-3232031 Dec 194-3331030 Sep 197-2930030 Jun 196-3030031 Mar 195-2731031 Dec 184-2831030 Sep 180-3030030 Jun 180-2929031 Mar 180-2525031 Dec 170-2121030 Sep 170-1825030 Jun 170-1419031 Mar 170-1313031 Dec 160-1313030 Sep 160-1210030 Jun 160-1210031 Mar 160-1012031 Dec 150-1010030 Sep 150-82030 Jun 151-62031 Mar 150-41031 Dec 140-21031 Dec 13000031 Dec 120000質の高い収益: IDOGENは現在利益が出ていません。利益率の向上: IDOGENは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: IDOGENは利益が出ておらず、過去 5 年間で損失は年間11.4%の割合で増加しています。成長の加速: IDOGENの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: IDOGENは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 7.2% ) と比較することは困難です。株主資本利益率高いROE: IDOGENは現在利益が出ていないため、自己資本利益率 ( -2166.6% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/07/11 12:33終値2023/07/06 00:00収益2023/03/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Idogen AB (publ) 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Klas PykNordea MarketsFilip EinarssonRedeye
お知らせ • Nov 26+ 2 more updatesIdogen AB (publ) to Report First Half, 2023 Results on Aug 23, 2023Idogen AB (publ) announced that they will report first half, 2023 results on Aug 23, 2023
お知らせ • Jul 08Nasdaq Stockholm Decides to Delist the Shares of Idogen from Nasdaq First North Growth MarketOn July 7, 2023, Idogen AB issued a with information that the Lund District Court had declared the company bankrupt. According to item 8.2.6 of the Nasdaq First North Growth Market Rulebook, the exchange may decide to delist the financial instruments of an issuer if the issuer is subject of insolvency. With reference to the above, Nasdaq Stockholm AB has decided to delist the shares of Idogen AB from Nasdaq First North Growth Market with immediate effect.
お知らせ • Nov 26+ 2 more updatesIdogen AB (publ) to Report First Half, 2023 Results on Aug 23, 2023Idogen AB (publ) announced that they will report first half, 2023 results on Aug 23, 2023
お知らせ • Nov 22Idogen AB (publ) Appoints Jan Holgersson to Its Board of DirectorsIdogen AB (publ) announced that Jan Holgersson, who has served for several years as scientific adviser to the company, has agreed to strengthen the company’s Board of Directors in the role as co-opted Board member. Jan Holgersson is a professor of Transplant Immunology at Gothenburg University, the Medical Director of the Tissue Typing and Stem Cell Laboratories at Sahlgrenska University Hospital in Gothenburg, where he was also formerly the Head of Clinical Immunology and Transfusion Medicine. His research focuses on understanding the immunological mechanisms that underlie the rejection of transplanted organs and tissues. Another important initiative has been supporting the development of diagnostics for detection and semiquantification of antibodies against the ABH blood group antigens and other tissue antigens (non-HLA). Jan Holgersson is also Chairman of the Board of VERIGRAFT AB, a Swedish biotech company. Jan has been part of the company’s efforts at a detailed survey of the mechanisms of action for the company’s technology platform.
Board Change • Nov 16High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 4 experienced directors. No highly experienced directors. Founder & Chairman of the Scientific Advisory Board Leif Salford is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Nov 02Idogen AB Announces Board ChangesIdogen AB announced that Agneta Edberg has been elected as new Chairman of the Board since the current Chairman of the Board, Joakim Söderström, has requested to resign from the Board of Directors at his own request as he has accepted a new position that is incompatible with being active in the Board of Directors of a public company. In addition, Niklas Wallett, who was elected to the Board of Directors at the same time as Joakim Söderström, has also requested to resign from the Board of Directors at his own request. In September 2022, both Joakim Söderström and Niklas Wallett were elected to the Board of Directors of Idogen. Joakim Söderström was elected to be the Chairman of the Board, replacing Agneta Edberg. Joakim Söderström has now requested to resign from the Board of Directors at his own request as he has accepted a new position that is incompatible with being active in the Board of Directors of a public company and he will resume his role as a shareholder. In addition, Niklas Wallett has also requested to resign from the Board of Directors at his own request to resume his role as a shareholder. Due to the above changes, the Board of Directors of Idogen has elected Agneta Edberg as new Chairman of the Board, effective from today. As consequence of these changes, the Board of Directors consists of Agneta Edberg, Chairman, Sharon Longhurst and Christina Herder, meaning that the Board of Directors retains a quorum. Proposal for election of a new Board of Directors will be submitted by the Nomination Committee in connection with the announcement of the notice of the Annual General Meeting 2023, at the latest.
お知らせ • Oct 15Idogen AB (Publ) Announces First Patient Enters Idogen's Hemophilia Study Under the Ido 8 ProgramIdogen AB (publ) announced that the first patient has been included in the Phase I/IIa clinical trial with ItolDC-028, the company's cell therapy that is part of its IDO 8 program. The patient was included at Oslo University Hospital, where the trial will be carried out under the management of professor and chief physician Pål Andre Holme. The patients that will be included in the study all have hemophilia A and should have developed antibodies to their treatment with factor VIII. They should also have undergone unsuccessful immune tolerance induction (ITI) treatment and still have inhibitors against factor VIII. The patient who has been enrolled in Norway will now undergo planned tests ahead of the apheresis process, the purpose of which is to collect the patient's white blood cells which are then used to manufacture the cell therapy. The white blood cells will be sent to the company's partner, Radboud University Medical Center (RUMC) in the Netherlands, where they will be processed using the company's patented technology. The overall objective of the therapy is toinduce a tolerance to factor VIII, which in turn means the patient can once again undergo factor VIII treatment without any problems.
お知らせ • Sep 28Idogen AB (publ) Announces Board ChangesOn September 6, 2022, Idogen held an Extraordinary General Meeting to elect Joakim Söderström as new chairman and Niklas Wallett to the board. They are both significant shareholders in Idogen and will now take an active role on the board to take the company to the next level. BioStock had a chat with newly elected Chair Joakim Söderström about his new role and his expectations.
お知らせ • Sep 21Idogen Receives Approval from the Regional Ethics Committee to Conduct Clinical Phase I/IIa StudyIdogen AB (publ) announces that the company has received approval from the Norwegian REK (Regionale komiteer for medicinsk og helsefaglig forskningetikk) in Oslo to conduct the clinical phase I/IIa study of their drug candidate within the IDO 8 program for patients suffering from hemophilia who have developed antibodies against their life-saving factor VIII treatment. The approval means that study activities can begin at the clinic and that the first patient can be enrolled in the study within short. Idogen has now received approval from the ethics committee in Oslo to conduct the company's phase I/IIa study in hemophilia with the drug candidate, ItolDC-028. The study is conducted under the leadership of professor and senor physician Pål Andre Holme. Shortly, the first patient will be able to be enrolled, after which the first step in the treatment will be possible to be carried out.
お知らせ • Sep 13Idogen Appoints Christina Herder as Acting CEOIdogen appointed Christina Herder as new acting CEO by the board of directors. Herder has for the past five years been a board member of Idogen and also has more than 30 years of experience in several senior positions in the pharmaceutical industry.
お知らせ • Sep 07Redeye Updates Their Analysis of Idogen as Company Approaches Clinical PhaseRedeye updated their analysis of Idogen as company approaches clinical phase Idogen AB (publ) is a company that is developing tolerogenic cell therapies with the aim to treat conditions or diseases caused by an unwanted immune response in the patient. As the company now approaches clinical phase with its most advanced development program IDO 8, Redeye is intensifying their coverage of Idogen and have published an updated analysis of Idogen AB. In summary, Redeye's report describes Idogen as a company developing novel treatments where there are large unmedical needs. In the most advanced program, IDO 8, the company has developed a cell therapy for patients with Hemophilia A, who have developed antibodies, a k a "inhibitors". Against their vital factor VIII treatment. The first clinical study within this program has, as previously communicated, obtained regulatory approval in both Sweden and Norway. The first patient is planned to be included in this phase 1/2a study during autumn. Another example that is highlighted in the analysis of the company's platform is the IDO T-program, where the researchers in the company is working to develop a new cell therapy for patients that are to have a kidney transplant. There is a risk that the patient develops an organ rejection and is currently treated, to minimize the risk, with immunosuppressants for long periods, which may lead to serious side effects. Example of side effects can be e.g. severe infections or cancer. A pre-treatment with Idogen's cell therapy, could counteract the undesired immune reponse that leads to a rejection. There are several more potential uses for cell therapies from the company as the technology platform is adaptable; as the tolerogenic cells may be adapted to several different types of antigens causing problems for the patient. The usage can thus be expanded to other diseases where the immune system attacks tissues or transplants in an unwanted way.
お知らせ • Aug 11Idogen AB (Publ) Announces CEO Executive ChangesIdogen AB (publ) announced that Anders Karlsson has decided to leave the company to move on to a CEO role in another Swedish biotechnology company. He will remain in his current position until 1 September 2022; the board is now starting a process to recruit a successor. Christina Herder, who has been a board member of the company for more than five years, has been appointed acting CEO while the recruitment of a new CEO is underway. She will retain her role on the board during this time.
お知らせ • Jul 29Idogen AB (publ) is Preparing to Start Clinical Phase 1/2A Study with IDO 8 in NorwayIdogen AB (publ) is working intensively on the preparations for the company's first clinical study with the cell therapy IDO 8 in patients with severe hemophilia A and is meeting a great deal of commitment at participating study centers. In Norway, the company's clinical trial center has come a long way in preparations for the study. Idogen has previously received approval from both the Swedish and the Norwegian Medicines Agency to start the study, and in Norway, patients who are suitable for inclusion have now been identified. Professor Pål Andre Holme, senior physician at Oslo University Hospital and clinical investigator in Idogen's study, says in an interview with BioStock that he expects to soon be able to start the study and hopes to start after the summer. What remains in Norway is an approval from the local ethics committee. The approvals the company received to start the study in Sweden and Norway are now being used to obtain a combined approval that includes all countries in the EU. For the UK, the approval process is based on the work done previously in Sweden and Norway.
Board Change • Apr 27No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 5 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Founder, Chairman of the Scientific Advisory Board & Director Leif Salford is the most experienced director on the board, commencing their role in 2009. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 20Idogen AB (publ) Announces Study Approval in Norway and SwedenIdogen AB (publ) has received the go-ahead from both the Swedish and Norwegian Medical Products Agencies to initiate a clinical phase I/IIa study with the cell therapy IDO 8 in hemophilia A. The study's primary purpose is to show that the treatment is safe and to obtain preliminary data on the potential treatment effect.
お知らせ • Apr 13+ 1 more updateIdogen Strengthens the Organization Before the Clinical Development PhaseIdogen (publbl) announced that the organization has been strengthened with several leang key roles before the companany's most advanced drug candidate enters the clinical development phase. The management team is thus expanded with competence and experience in both early drug development and clinical trials. In March 2022, Idogen received approval from the Medical Products Agency to initiate a clinical phase 1/2a study in the development program IDO8, a potentially revolutionary cell therapy for patients with severe hemophilia A who have developed antibodies to their vital treatment with coagulation factor VIII. The study will be conducted at several testing centers in Europe and before the start, the company is now strengthening the organization with three new employees.
お知らせ • Apr 11Idogen AB (Publ) Receives Approval from the Norwegian Medicines Agency, Noma, for the Start of Clinical Phase 1/2A Study with IDO 8Idogen AB (publ) received approval from the Norwegian Medicines Agency, NoMA, to ben recruitment for its clininical phase 1/2a study with IDO 8, a completely new type of cell therapy for patients with severe hemophilia A who have developed antibodies to their treatment with coagulation factor VIII. The Swedish Medical Product Agency has already previously approved the phase 1/2a study and patient recruitment in Sweden will begin as soon as the authority has formally approved the local trial center where the study is to be carried out. The approval from NoMA now gives the go -ahead to start patient recruitment in Norway as well. The plan is for the study to be carried out in several European countries. Idogen's cell therapy IDO 8 is tailored for each individual patient in a GMP-certified facility at the company's Dutch manufacturing partner Radboud University Medical Center (RUMC). The study has been designed in dialogue with the regulatory authorities in the Nordic countries and the goal is to evaluate the safety of IDO 8 and to follow signals of treatment effect in patients.
お知らせ • Mar 29Idogen Receives Approval from the Swedish Medical Products Agency for the Clinical Phase I/IIa Study with IDO 8Idogen recently announced that they have received approval from the Swedish Medical Products Agency for the clinical phase I/IIa study with IDO 8. The cell therapy is aimed at patients with severe haemophilia A who have developed antibodies to their substitution therapy with coagulation factor VIII. BioStock contacted Professor Jan Astermark, Principal Investigator in the clinical study, to find out more about the unmet medical need of these patients.
お知らせ • Feb 15Idogen AB (publ) has completed a Composite Units Offering in the amount of SEK 50.425465 million.Idogen AB (publ) has completed a Composite Units Offering in the amount of SEK 50.425465 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 16,478,910 Price\Range: SEK 3.06 Transaction Features: Rights Offering
お知らせ • Jan 12Idogen AB (Publ) Submits Application to Norwegian Medicines Agency to Begin Clinical Phase 1/2A Study of the Advanced Cell Therapy Treatment IDO 8 in NorwayIdogen AB announced that in addition to its Swedish application, it has also sub-mitted an application to the Norwegian Medicines Agency, NoMA, to be able to begin its clinical phase 1/2a study of the company's most advanced cell therapy treatment IDO 8 in Norway. IDO 8 aims to create tolerance for factor VIII and thus enable ongoing substitu-tion treatment with coagulation factor VIII - a life-saving drug treatment for hemophilia A against which many patients develop antibodies. The aim of the planned phase 1/2a study, which was designed in close dialogue with clinical experts and regulatory authorities in the Nordic region, is to evaluate the safety of IDO 8 and follow signals of treatment effect in patients. Given that the application is approved by NoMA without adjustments, the study is planned to start during the second quarter of 2022. Idogen's cell therapy is tailored for each individual patient in a GMP-certified facility at the company's manufacturing partner Radboud University Medical Center (RUMC) in the Netherlands. The therapy is based on the patient's own cells and is expected to have a favorable safety profile and the opportunity to create a long-term treatment effect.
お知らせ • Dec 22Idogen Submits Clinical Trial ApplicationIdogen submitted a clinical trial application to the Swedish Medical Products Agency to initiate a clinical phase I/IIa study with the cell therapy IDO 8 in patients with haemophilia A who have developed antibodies to their treatment. Once the application has been reviewed and approved, the study can be initiated, which is expected to be in the second quarter of 2022.
お知らせ • Dec 18Idogen AB Submits an Application to the Swedish Medical Products Agency to Initiate A Clinical Phase 1/2A Study of the Cell Therapy Treatment IDO 8Idogen AB announced that it has submitted a clinical trial application to the Swedish Medical Products Agency (MPA) to begin its clinical phase 1/2a study of the company's most advanced cell therapy treatment, IDO 8. IDO 8 aims to create tolerance to factor VIII, thereby enabling ongoing substitution treatment withcoagulation factor VIII a vital treatment in hemophilia (hemophilia A) against which many patients develop antibodies. The aim of the planned phase 1/2a study, which has been designed in close dialogue with the regulatory authorities in the Nordic countries, is to evaluate the safety of IDO 8 and to monitor patients forsignals of a clinical treatment effect. The planned start date of the trial is dependent on the MPA review process, but it is anticipated the study, once approved, will be initiated in the second quarter of 2022. Idogen's cell therapy is tailored for each individual patient in a GMP-certified laboratory at the company'smanufacturing partner Radboud University Medical Center in the Netherlands. The therapy is based on the patient's own cells and is therefore expected to have a favorable safety profile and to create a long-term treatment effect. The company is now initially submitting the application to start the phase 1/2a study to theMPA.
お知らせ • Dec 08Idogen AB (publ) Completes the Optimization of the GMP Manufacturing Process for the First Clinical Study with Its Tolerogenic Cell Therapy IDO 8Idogen AB announces that it has successfully maximized the antigen levels in the cell therapy IDO 8 that the body should learn to recognize and tolerate. This is considered to be an important feature in order to obtain a good treatment effect. The IDO 8 treatment is aiming to create tolerance for ongoing substitution treatment with coagulation factor VIII, a vital drug for hemophilia (hemophilia A) which in many patients is inactivated as a result of undesired immune reactions. The company will shortly submit a clinical trial application to start the first study in patients. Subject to required regulatory approvals, the study is planned to start during the second quarter of 2022. A successful tech transfer and scale-up of the manufacturing process for Idogen's cell therapy has been followed by extensive work aimed at optimizing, documenting and qualifying the manufacturing process for the planned first clinical study. The company's manufacturing partner, Radboud University Medical Center (RUMC) in the Netherlands, a manufacturer of cell therapies, has now optimized and qualified the manufacturing process, achieving product properties equivalent to those generated when IDO 8 was manufactured in Idogen's own research laboratory. This has been achieved through an effective collaboration between RUMC and Idogen. Idogen's cell therapy will now be tailored for each individual patient in a GMP-certified laboratory at the company's partner Radboud University Medical Center in the Netherlands. The proprietary treatment is based on patients own cells, differentiated into dendritic cells using Idogen's unique tolerance inducers and the specific antigen that the body's immune system must learn to tolerate.
Recent Insider Transactions • Oct 06CEO & MD recently bought kr144k worth of stockOn the 5th of October, Anders Karlsson bought around 70k shares on-market at roughly kr2.06 per share. This was the largest purchase by an insider in the last 3 months. This was Anders' only on-market trade for the last 12 months.
お知らせ • Feb 26Idogen AB Receives Confirmation the European Patent Office Intends to Grant A Patent ApplicationIdogen AB has received confirmation that the European Patent Office (EPO) intends to grant a patent application which supports and covers the company's tolerogenic cell therapy's application to the severe bleeding disorder, hemophilia A. This patent application was submitted in 2016 and will provide additional protection to the broader patent application for Idogen's technology which in December 2020 was extended via an International (PCT) application. When the patent (Patent Application No. EP16710978.4) is granted, it will protect this technical space until 2036. The final grant of this patent by the EPO is expected to occur within two to three months following the completion of routine formalities by Idogen. A similar application is pending in the US. The granted patent will provide important complementary protection to that sought via the International (PCT) application for Idogen's new, innovative method for cell therapy that was filed in December 2020. That patent application will, following grant, provide the company with a patent protection and market exclusivity until 2040.
Is New 90 Day High Low • Feb 23New 90-day low: kr2.99The company is down 16% from its price of kr3.55 on 25 November 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.
お知らせ • Feb 09Idogen AB (publ) Announces Executive ChangesIdogen AB (publ) announced that Åsa Schiött was appointed new Chief Scientific Officer (CSO), Christina Brattström new Chief Medical Officer (CMO) and Vicky Venizelos Chief Regulatory Officer (CRO).
Is New 90 Day High Low • Dec 28New 90-day low: kr3.08The company is down 41% from its price of kr5.18 on 29 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 12% over the same period.
Is New 90 Day High Low • Dec 08New 90-day low: kr3.27The company is down 42% from its price of kr5.68 on 09 September 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Nov 19New 90-day low: kr3.63The company is down 42% from its price of kr6.24 on 20 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 10.0% over the same period.
Is New 90 Day High Low • Oct 16New 90-day low: kr3.98The company is down 43% from its price of kr6.98 on 17 July 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Sep 28New 90-day low: kr5.06The company is down 5.0% from its price of kr5.30 on 30 June 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period.